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Available online 26 August 2016The derivation of dopaminergic neurons from induced pluripotent stem cells brings new hope for a patient-spe-
ciﬁc, stem cell-based replacement therapy to treat Parkinson's disease (PD) and related neurodegenerative dis-
eases; and this novel cell-based approach has already proven effective in animal models. However, there are
several aspects of this procedure that have yet to be optimized to the extent required for translation to an optimal
cell-based transplantation protocol in humans. These challenges include pinpointing the optimal graft location,
appropriately scaling up the graft volume, and minimizing the risk of chronic immune rejection, among others.
To advance this procedure to the clinic, it is imperative that a model that accurately and fully recapitulates char-
acteristics most pertinent to a cell-based transplantation to the human brain is used to optimize key technical as-
pects of the procedure. Nonhuman primates mimic humans in multiple ways including similarities in genomics,
neuroanatomy, neurophysiology, immunogenetics, and age-related changes in immune function. These charac-
teristics are critical to the establishment of a relevant model in which to conduct preclinical studies to optimize
the efﬁcacy and safety of cell-based therapeutic approaches to the treatment of PD. Here we review previous
studies in rodent models, and emphasize additional advantages afforded by nonhuman primate models in gen-
eral, and the baboon model in particular, for preclinical optimization of cell-based therapeutic approaches to the
treatment of PD and other neurodegenerative diseases.We outline current unresolved challenges to the success-
ful application of stem cell therapies in humans and propose that the baboon model in particular affords a num-
ber of traits that render it most useful for preclinical studies designed to overcome these challenges.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
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PD is a neurodegenerative disorder characterized by the selective
loss of dopamine-producing neurons in the substantia nigra pars
compacta (SNc) (Carlsson, 1959; Ferri et al., 2007). Rigidity, postural in-
stability, bradykinesia, and resting tremor are the cardinal symptoms
(Parkinson, 1817; Dauer et al., 2002), but 50–80% of patients with PD
also suffer cognitive impairments such as dementia (Litvan et al.,
2012; Hely et al., 2008), personality changes including depression, anx-
iety, and passivity (Fahn, 2010), and other non-motor symptoms such
as sleep irregularity, incontinence, constipation, and fatigue, which typ-
ically persist despite treatment (Chaudhuri and Quinn, 2006). Symp-
toms emerge when approximately 50–60% of the SNc neurons are
lost, corresponding to an 80–85% deﬁcit in dopamine levels within the
striatum (Wirdefeldt et al., 2011). By the time of death, typically 70–
90% of the SNc neurons have been lost (Davie, 2008; Bernheimer et al.,
1973; Riederer and Wuketich, 1976).
There are no curative agents for PD, and all available treatments tar-
get only the symptoms of the disease. Stem-cell based therapies repre-
sent a novel and promising approach to mitigate this disease, however
the efﬁcacy and safety of this approachmust be optimized prior to its in-
troduction into the clinic including the use of relevant animal models.
Due to their close phylogenetic proximity to humans, nonhuman pri-
mates (NHPs) provide the most accurate models for such preclinical
studies. Of particular relevance to transplantation of stem cell-derived
neurons into the brain for the treatment of Parkinson's disease (PD),
NHPs accurately mimic key neuroanatomical, neurophysiological, im-
munological, and genetic features of humans. AmongNHP species avail-
able for use in biomedical research, the baboon offers several speciﬁc
characteristics that render it the most promising NHPmodel for studies
of cell-based therapies for PD.
Currently, dopamine replacement therapy is the most common
treatment for PD (Tarsy, 2015). The immediate precursor to dopamine,
L-dopa, is administered to patients because dopamine itself is incapable
of crossing the blood brain barrier (Carlsson, 1959). However, L-dopa in-
duces dyskinesia (Calabresi et al., 2010), increased coronary artery dis-
ease (Rogers et al., 2003), emesis in humans (Tarsy, 2015; Bieger et al.,
1977; Sanger and Andrews, 2006), and some suggest it accelerates neu-
ronal degeneration (Parkinson Study, 2000; Whone et al., 2003; Group,
2002). More recently, deep brain stimulation of the subthalamic nucle-
us, globus pallidus, or pedunculopontine nucleus has been used to treat
PD (Kumar et al., 1998; Stefani et al., 2007). While deep brain stimula-
tion has proven effective for eliminating some of the motor symptoms
of PD, it has shown limited capacity to reduce non-motor symptoms
(Fasano et al., 2012). It also does not effectively treat axialmotor deﬁcits
such as postural instability, and the efﬁcacy of deep brain stimulation
declines as the disease progresses (Kleiner-Fisman et al., 2003).
As an alternative to dopamine replacement therapy and deep brain
stimulation, PD may be treated by replacing lost neurons with neural
tissue derived from progenitor cells. Prior to the advent of pluripotent
stem cells, clinicians attempted to treat PD by transplanting cells de-
rived from a variety of heterologous tissue sources into the striatum
(Bjorklund and Kordower, 2013). Fetal ventral mesencephalon tissue
demonstrated the most success in preclinical studies in rodents, but ul-
timately failed to signiﬁcantly reduce parkinsonism in double-blind
clinical trials (Freed et al., 2001, 2011; Olanow et al., 2003). There are
at least three factors potentially culpable for the failure of previous
human clinical trials of cell-based transplantation therapy for PD: 1.)the use of a heterogeneous cell population as a tissue source, 2.)
transplanting tissue to a heterotopic graft site, and 3.) the lack of an op-
timized immunosuppressive regimen (Bjorklund and Kordower, 2013;
Lindvall, 2013).
The discovery of pluripotent stem (iPS) cells, which are derived from
a patient's own cells, provided an avenue to potentially mitigate im-
mune rejection while simultaneously circumventing the ethical hin-
drances of using tissues from aborted fetuses. There are a number of
studies reporting the ability to differentiate iPS cells into dopamineneu-
rons and subsequently transplant those neurons into rodent brains (Xi
et al., 2012; Morizane et al., 2013; Sundberg et al., 2013; Hallett et al.,
2015). Although these studies used tissues derived from the host, re-
sults demonstrating tolerance of the grafts by the host immune systems
are inconsistent (Morizane et al., 2013; Hallett et al., 2015; Soldner et al.,
2011; Guha et al., 2013; Araki et al., 2013; Kaneko and Yamanaka, 2013;
Kruse et al., 2015; Itakura et al., 2015; Xian and Huang, 2015). Further,
as mouse models of PD typically do not display non-motor symptoms
(Table 1), these studies were unable to test the ability of stem cell-de-
rived tissue grafts to treat all deﬁcits associatedwith the disease. Never-
theless, these studies did demonstrate that an autologous dopamine
neuron graft is capable of signiﬁcantly reducing themotor defects in ro-
dents whosemidbrain dopamine neurons had been genetically or phar-
macologically lesioned.
More recently, work has been performed in theNHP species,Macaca
fasicularis (the crab-eating macaque), in which autologously
transplanted iPS-derived dopamine neurons were able to survive and
restore motor deﬁcits for up to 2 years (Hallett et al., 2015). However,
the degree to which studies investigating immune tolerance inMacaca
fasicularis are able to accurately predict outcomes in humans remains
a question (see Section 3 of this review). Further, while some non-
human primate species have been shown to display non-motor symp-
toms after MPTP treatment (Hantraye et al., 1996), the ability for iPSC-
derived tissue grafts to restore the non-motor deﬁcits in MPTP treated
monkeys remains untested. Therefore, questions still remain as to the
safety and efﬁcacy of cell-based therapies for PD. Clinical trials have
not yet been attempted in humans (Freed et al., 2011), but the inconsis-
tent results of animal studies conducted to date exemplify the need for
further, more informative NHP preclinical studies to optimize the safety
and efﬁcacy of cell-based therapies for PD.
The possibility of a cell-based replacement approach based on deri-
vation of patient-speciﬁc iPS cells (Takahashi et al., 2007) and the sub-
sequent directed differentiation of these cells into transplantable
dopaminergic neurons (Soldner et al., 2009) has engendered renewed
optimism that an effective cell-based treatment for PD can be devel-
oped. iPS cells circumvent the ethical impediments that accompany
the use of tissues derived from aborted fetuses (Freed et al., 2001;
Olanow et al., 2003, 1996), or from human embryos as would be re-
quired for an embryonic stem cell based approach (McHugh,
2004). However, several technical issues surrounding the develop-
ment of an optimal cell-based protocol for the treatment of PD
remain largely unresolved, including 1.) the determination of an
optimal target graft site, 2.) the identiﬁcation and puriﬁcation of
the appropriate neuronal subtype to be transplanted, and 3.) deter-
mination of an optimal immunosuppressive regimen necessary to
the extent needed to support an autologous transplantation
approach. Additionally, long-term studies must be conducted to in-
terrogate both the immunogenic and tumorigenic potentials of the
transplanted cells, as well as to assess the full range of therapeutic
Table 1
Comparison of key features of a transplantation model for Parkinson's disease.
Rodent New World 
Monkey
Old world monkey Hominidae
Mouse Rat Marmoset Macaque Baboon Human
Genome identity with  
humans 48–66%(46, 47) 44–64%(46, 47) 92%(48) 92%(49) 100%
MHC class I  sequence 
identity with humans 82%(167) 90–99%(171) 90–99%(173) 100%
Physical separation of 
caudate and putamen No No Yes Yes Yes Yes
SNc TH+ neurons (×103) 12.7(60)–15.7(59) 29.9(60) 203(60) 259(60) 382(60)
Grey matter to white 
matter ratio 11.22(121) 6.38(121) 3.16(121) 1.91(121) 1.083(121, 289)
3.0 (young)–1.0 
(aged)(290)(121)
Midbrain response to 
aversive stimuli
VTA 
responds(98) VTA responds(291)
VTA and SNc 
respond(96, 196)
VTA(292) and 
SNc(293) respond
IgG subclasses I, IIA, IIB(294) I, IIa, IIb, IIc(295) I,II, IV(185) I, II, III, IV(185) I, II, III, IV(185)
Relationship of IL–1 
levels with age +(296) +‡(297, 298) No assoc.(201) +(195, 196) 
Relationship of IL–6 
levels with age –(299, 300) –(201) +(204) +(193)
Relationship of IL–8 
levels with age –(301, 302)
No assoc.(200)
+(194)
Relationship of IL–10 
levels with age +(303) +(201) No assoc.(204) +(195)(196) 
Relationship of C–
reactive peptide levels 
with age
No 
Assoc.(200) +(204) +(193)
Relationship of TNF–α 
levels with age –(299, 300) +(298) –(201) +(204) +(195, 196)
Relationship of TGF–ß1 
levels with age ++(297) +(304) –(205) –(197)
Relationship of DHEA 
levels with age
–(305)
–(205) –(198)
MPTP sensitivity Insensitive(228) Insensitive(229) Sensitive(240) Sensitive(241) Sensitive Sensitive(243)
MPTP impairments H/B, T(306) H/B, T(307)C(308)
H/B R, T, P, 
C(265) H/B R, T, P, C(249)
H/B(256)R(256), 
T(256), P(257), 
C(41) H/B R, T, P, C(259)
Dissimilar From Human Similar to Human
† mRNA was elevated, 
protein status is 
unknown.
H/B= hypokinesia/bradykinesia
‡detected elevated IL–1 in rat hippocampus and spleen with age but nowhere else in the brain 
R= Rigidity
nor in serum
T= Tremor
P= Postural 
Instability
C= Cognitive Impairment 
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of non-motor deﬁcits).
Several advantages of NHPs as a preclinical model emerge as one ex-
amines the consequences of the evolutionary proximity of NHPs to
humans. For example, mice and rats share only 66% (M. G. S.
Consortium, 2002) and 64% (Nature, 2004) genome identity with
humans, respectively. Macaques (Caccone and Powell, 1989) and ba-
boons (Rogers andHixson, 1997), on the other hand, both share 92% ge-
nome sequence identity with humans (Table 1). NHPs also share
signiﬁcant neuroanatomical similarities with humans, a characteristic
that is particularly germane to the identiﬁcation of an optimal target
graft site. Additionally, similarities between the immunogenetics andage-related changes in immune function found in humans and NHPs af-
ford relevance to the use of NHP models for testing potential immune
rejection and/or potential tumorigenic outcomes following cell trans-
plants. Finally, the longevity and cognitive abilities of NHPs are much
more similar to those found in humans than are those found in rodent
species, and this is critical for accurate assessments of the capacity of
cell-based therapies to provide long-term relief from both the motor
and non-motor symptoms of PD.
The great apes (chimpanzees, gorillas, orangutans) share the
greatest genetic similarity with humans (Bontrop and Watkins, 2005),
a similar brain volume and organization, and an 86% sequence identity
in the major histocompatibility complex (MHC) class I coding region
355D.A. Grow et al. / Stem Cell Research 17 (2016) 352–366(Kelley et al., 2005). However, the United States National Institutes of
Health has announced that the use of chimpanzees in biomedical re-
search is being abated (Cohen, 2007; Kaiser, 2013). Therefore, we pres-
ent here a discussion of themost common andmost relevant preclinical
models excluding the great apes.We review studies performedwith the
use of rodents and describe advantages of NHPs in general and baboons
in particular in regard to the neuroanatomical and neurophysiological
characteristics (Section 2), immune system biology (Section 3), and
motor and non-motor manifestations of the MPTP lesion (Section 4)
needed to validate translation of a stem cell transplantation therapy
for PD to the clinic.We conclude that NHPmodels afford unique advan-
tages over rodent models that are critically important for the accurate
recapitulation of the PD disease state and optimization of the efﬁcacy
and safety of cell-based approaches to treatment of this disease. Finally,
we propose that among available NHPmodels, the baboon provides the
most accurate representation of human conditions relevant to the treat-
ment of PD (Section 5).
2. The NHP for transplantation therapy: addressing the graft
location
An important aspect of successful cell transplantation therapy for
PD is the restoration of the complete physiological neuronal network
(Gaillard and Jaber, 2011; Shinoyama et al., 2013). The standard proto-
col for transplanting dopamine neurons into a PD model involves
grafting new neurons into the striatum, a heterotopic graft location
(Laguna Goya et al., 2008). New dopamine cells grafted into the stria-
tum lack the inputs that their physiological endogenous counterparts
receive. Accordingly, it is possible that heterotopic transplantation of
dopamine neurons may fail to restore behavioral defects that arise due
to a dopamine deﬁcit in areas outside the striatum. As opposed to
striatal grafts, homotopic grafts into the SNc could be optimally posi-
tioned to receive physiological signaling. However, it is unknown to
what extent these new axons will be capable of projecting through
the adult humanbrain, towhat extent such a graftwill be capable of sur-
viving long-term in the SNc, or to what extent homotopic grafts will be
capable of restoring striatal and extrastriatal dopamine deﬁcits. When
considering the graft location, preclinical studies must weigh these fac-
tors against the potential absence of these signaling inputs and how that
absence may affect the behavior of dopamine neurons and ultimately,
the behavior of the animal. These and other neuroanatomical and neu-
rophysiological similarities shared by NHPs and humans render NHPs
the optimal availablemodels for analyzing the relative efﬁcacy of differ-
ent putative target graft sites. In this section, we review the speciﬁc ef-
ferent connections of the SNc in rodents (2.1) and NHPs (2.2). We also
examine similarities and differences among rodents, NHPs, and humans
in electrophysiological properties (2.3 and 2.4), such as neuronal ﬁring
rate and response to rewarding or aversive stimuli (2.4 and 2.6). In
2.7, we discuss the advantages and disadvantages of homotopically
and ectopically located transplant sites, and propose that the baboon
is best suited to test the efﬁcacy of various transplant locations based
on its particular set of neuroanatomical and neurophysiological
characteristics.
2.1. SNc efferents in rodents
In rodents, efferents of the SNc innervate the striatum (Roeper,
2013). Leaving the SNc, they follow the median forebrain bundle ros-
trally until they penetrate the densewhitematter tract known as the in-
ternal capsule. At this point, the ﬁbers either ascend around the
perimeter of the dorsal pallidum, descend around the ventral pallidum,
or enter the ventral pallidumdirectly and cut across it en route to thepu-
tamen, climbing the striatalfugalWilson's Pencils. Dopaminergic projec-
tions to the globus pallidus, subthalamic nucleus, substantia nigra pars
reticulata and the prefrontal cortex originate primarily in the VTA or
retrorubral ﬁeld (Roeper, 2013). Therefore, in the rodent, geographicalborders delineate dopamine neuron nuclei in the ventral midbrain
with each nucleus containing within it neurons that share similar
hodology (speciﬁc pathways and connectionswithin the neuroanatom-
ical circuit) and immunoreactivity.
2.2. SNc efferents in NHPs and humans
Organization of the primatemidbrain differs from that of the rodent.
One considerable difference is the disproportionate expansion in the
number of dopamine cells in the primate SNc (Duzel et al., 2009). The
rat SNc contains up to 15 × 103 TH+ neurons (Nair-Roberts et al.,
2008; Hardman et al., 2002), whereas the marmoset has twice that
amount and the macaque has up to 203 × 103 TH+ neurons
(Hardman et al., 2002). Baboons, which have up to 260 × 103 TH+ neu-
rons in the SNc, are the closest old world NHP to humans (Hardman et
al., 2002), which have up to 382 × 103 TH+ neurons in the SNc
(Hardman et al., 2002) (Table 1). These disparities in the number of
TH+ neurons between species are disproportionate in that they cannot
be accounted for by linear correlationwith overall brain size, and there-
fore may partially explain why it has been challenging to restore motor
functions with stem cell grafts in patients with PD or in NHP PDmodels
when cell-based treatments have produced encouraging results in ro-
dent models (Sanchez-Pernaute et al., 2008; Kriks et al., 2011; Hargus
et al., 2010; Thompson et al., 2009; Grealish et al., 2010, 2014. Also un-
like rodents, primates show no geographic boundaries that contain
within them a group of midbrain dopamine neurons that share
hodological, and immunoreactive characteristics (Lynd-Balta and
Haber, 1994; Joel and Weiner, 2000). In addition, the primate striatum
is split by the internal capsule into the caudate nucleus and the putamen
(Fig. 1A–E). Thus, in addition to the striatal connections mentioned
above, some SNc efferent ﬁbers do not penetrate the internal capsule
in the primate brain, but instead project rostrally through the medial
forebrain bundle until they reach the reticular nucleus of the thalamus,
which they follow as they extend to their destination in the caudate nu-
cleus (Prensa et al., 2000).
Perhaps one of the most striking neuroanatomical features of pri-
mates is the enhanced presence of extrastriatal innervation from the
SNc. In both NHPs (Bjorklund and Dunnett, 2007; Mark Williams and
Goldman-Rakic, 1998) and humans (Prensa et al., 2000; Björklund and
Dunnett, 2007), the SNc projects to structures other than the striatum
(Duzel et al., 2009) (Fig. 2), such as the globus pallidus (Smith et al.,
1989; Parent et al., 1990), the subthalamic nucleus (Lewis et al.,
1988), and the prefrontal cortex (Sharman et al., 2000). Speciﬁcally, ef-
ferents from the SNc to the dorsolateral frontal cortex may be unique to
primates (MarkWilliams andGoldman-Rakic, 1998) (Fig. 2). As a result,
NHP models of PD and humans with PD may display consequences of
dopamine depletion in the extrastriatal structures that are not observed
in rodents. For example, type D2 dopamine receptors are prominent in
the frontal cortex of humans (Joyce et al., 1991; Murray et al., 1994)
and loss of dopamine in this region may result in cognitive deﬁcits in
humans (Diamond and Baddeley, 1996). The frontal cortex receives do-
pamine primarily from the VTA in rodents (Roeper, 2013), and thus do-
pamine supply to this area may be relatively intact in rodent models of
PD, whereas in primates both the SNc and the VTA supply dopamine to
the frontal cortex (Duzel et al., 2009). To date, it is not known whether
there is a PD-mediated dopamine deﬁcit in the frontal cortex of PD pa-
tients, and/or how that deﬁcit might be involved in PD symptoms such
as cognitive decline. Further, neurons in the external globus pallidus
(GPe), internal globus pallidus (GPi), and subthalamic nucleus (STN)
also express dopamine receptors and respond to dopamine agonists
and antagonists in humans (Murray et al., 1994).
The exigent nature of extrastriatal dopamine was demonstrated in a
study of rhesus monkeys, in which all MPTP-lesioned monkeys exhibit-
ed striatal dopamine depletion, but only those that also displayed
extrastriatal dopamine depletion presented with parkinsonism (Piﬂ et
al., 1990). Further, it has been demonstrated in humans that
Fig. 1. Comparative anatomy of the putamen and caudate nucleus. A. In the rodent, the putamen (PU) and caudate nucleus (CA), the primary targets of SNc dopamine neurons, are
physically merged and therefore indistinguishable (caudoputamen; outlined in red). B–E. In primates, the ﬁbers of the internal capsule (IC) split the CA and PU (outlined in red) into
two separate structures. F–J. Coronal views of the basal ganglia, all aligned to the same scale to allow direct comparisons of the structures across species. Among commonly used
transplantation models, the baboon best represents the size and spatial distribution of the human caudate and the putamen. Images are printed with permissions from the following
agencies: Mouse (Lein et al., 2007; Allen Mouse Brain Atlas, 2015), Marmoset (Yuasa et al., 2010), Rhesus (Mikula, 2013), baboon (Davis and Huffman, 1968), human (adapted with
permission from http://www.brains.rad.msu.edu, and http://brainmuseum.org, supported by the US National Science Foundation; (Sudheimer et al., n.d.).
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bens, and the substantia nigra pars reticulata are all deprived of dopa-
mine in patients with PD (Hornykiewicz, 1998). Thus, PD-mediated
dopamine depletion may have effects outside the striatum. However,
the capacity for animals models to recapitulate extrastriatal deﬁcits re-
mains a debate (Jan et al., 2000). While, rhesus macaques have shownFig. 2. Efferent targets of SNc and VTA dopamine neurons in the rodent and primate. A chart
compares it to connections discovered in nonhuman primates and humans (primates). Nigra
nigralstriatal collaterals in the rodent. The primate SNc contains neurons that project dedic
directly to the olfactory bulb (4). This pathway has yet to be found in nonhuman primate
primarily in the VTA (thick blue arrow), whereas in primates, the amygdala receives dopam
dopaminergic innervation to the nucleus accumbens (6) and to the frontal cortex (7), howevea signiﬁcant increase in burst ﬁring from the neurons in the GPi
(Wichmann et al., 1999) and STN (Galvan et al., 2014) as a result of
dopamine depletion, both rhesus macaques and rodents counterintui-
tively failed to show a signiﬁcant change in ﬁring activity in the GPe
(Hadipour-Niktarash et al., 2012). The lack of response to MPTP in the
rhesus GPe is corroborated by previous studies demonstrating thatthat compares neuroanatomical connections discovered in mice and rats (rodents), and
l projections to the subthalamic nucleus (1) and globus pallidus internal (2) arise from
ated ﬁbers to these nuclei (3). In the rodent, there exists a nigral efferent that projects
s or humans (5). In the rodent, dopaminergic innervation of the amygdala originates
inergic input primarily from the SNc (thick orange arrow). The primate SNc also sends
r, these pathways are minimal or absent in the rodent.
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rhesus monkeys (Parent et al., 1990; Schneider and Dacko, 1991). The
ﬁring rates of extrastriatal neurons in MPTP-treated baboons have not
been interrogated, however, MPTP-treated baboons do demonstrate a
loss of TH+ ﬁbers in extrastriatal structures such as the GPe (Varastet
et al., 1994), suggesting that they may better model the parkinsonian
state than do rodents or rhesus macaques.
2.3. SNc afferents and action potential behavior in rodents
Dopamine neurons receive excitatory glutamatergic input from the
subthalamic nucleus, the pedunculopontine nucleus, and the neocortex,
as well as inhibitory GABAergic inputs from the substantia nigra pars
reticulata, the striatum, and the globus pallidus (Lobb et al., 2011). In
humans (Ramayya et al., 2014), NHPs (Bayer et al., 2007), and rodents
(Grace and Bunney, 1984a, 1984b), midbrain dopamine neurons are ca-
pable of displaying at least two modes of action potential behavior:
tonic ﬁring at 2–10 Hz, or burst (high frequency action potential activi-
ty) ﬁring at N12.5 Hz. Rhythmic activity results in tonic dopamine re-
lease, and this steady-state dopamine tone is believed to establish
sensitivity to thephasic dopamine release that occurs during burstﬁring
(Grace, 1991). Burst ﬁring, on the other hand, occurs when a dopamine
neuron ﬁres a cluster of action potentials in short proximity. The result
is a short-term (phasic) increase in the amount of dopamine release per
action potential (Gonon, 1988). The ﬁring rate for optimal dopamine re-
lease is species dependent. Dopamine cells in the rat release the highest
amount of dopamine when ﬁring at 14 Hz (Gonon, 1988), and these
neurons usually do not ﬁre faster than 15 Hz (Grace and Bunney,
1984a, 1984b). Further, electrophysiological experiments carried out
on rodent slice preparations in vitro, in which a substantial portion of
the SNc's afferents are lost, demonstrated thatmidbrain dopamine neu-
rons require these afferents to produce burst activity (Grace and Onn,
1989). The fact that dopamine cells depend on afferent activity in
order to burst suggests it is possible that species differences in ﬁring
properties of dopamine neurons is a result of contrasting hodological
proﬁles.
Differences in burstﬁring properties, efferent connections, and affer-
ent connections may result in species differences in the type of signals
SNc neurons are capable of encoding. Therefore, species differences in
the types of behaviors that illicit a burst in dopamine cellsmay be emer-
gent properties arising from corresponding species differences in effer-
ent and afferent signaling. For example, in the rodent, dopamine
neurons in only the VTA will burst when an aversive stimulus is pre-
sented (Brischoux et al., 2009; Lammel et al., 2011), whereas in pri-
mates, both the VTA and the SNc contain dopamine neurons that may
burst in response to aversive stimuli (Matsumoto and Hikosaka, 2009;
Pignatelli and Bonci, 2015; Lammel et al., 2011; Jensen et al., 2003;
Seymour et al., 2004).
2.4. SNc afferents and action potential behavior in NHPs and humans
Dopamine neurons in primates differ somewhat from those of ro-
dents in burst frequency and in the type of stimuli that illicit a burst. Do-
pamineneurons of the newworld primate, Callithri jacchus (marmoset),
release a maximal amount of dopamine in the striatum when ﬁring at
20 Hz (Cragg et al., 2000) or almost 1.5× higher than the rates observed
in rodents. Burstﬁring in the oldworldmonkey,Macacamulatta (rhesus
macaque), is even higher and has beenmeasured as high as 36 Hz with
mean burst rates of approximately 22Hz (Bayer et al., 2007;Matsumoto
and Hikosaka, 2009; Hong and Hikosaka, 2014; Schultz, 1986; Schultz
and Aebischer, 1983). The only study to measure burst frequency in
the human SNc reported a frequency of 16 Hz (Ramayya et al., 2014),
however, these data were obtained from a patient with late-stage PD
and it is unknown howPD affects the burst frequency of dopamine neu-
rons in humans. Nevertheless, it is clear that SNc dopamine neuronsshow species-dependent ﬁring properties that may be a consequence
of their particular sets of afferents.
2.5. The source of dopamine release after a reward prediction error in
rodents
Dopamine neurons will also burst when an individual is presented
with a conditioned stimulus that has been paired with a reward; and
dopamine neuronswill pause activity if that conditioned stimulus is de-
livered with no accompanying reward (reward prediction error; RPE)
(Schultz, 1997, 1998). This RPE signal is signiﬁcantly curtailed in rodent
models of PD (Pessiglione et al., 2006). However, if the parkinsonian ro-
dent is administered dopamine agonists or L-dopa, which are the most
common treatments in PD, the RPE response is signiﬁcantly protracted
(Pessiglione et al., 2006). This observed disruption in reward encoding
in rodent models of PD may have clinical signiﬁcance in that it has
been offered as an explanation for why humans with PD experience
symptoms such as anhedonia (presumably from reduced RPE signaling)
(Loas et al., 2012) and dopamine agonist-induced side effects, such as
gambling addiction and hypersexuality (presumably from augmented
RPE signaling) (Moore et al., 2014). However, RPE signal itself has not
been investigated in MPTP treated NHPs nor in humans with PD.
NHPs offer an advantage over rodents in this type of research be-
cause there exist striking neuroanatomical similarities between NHPs
and humans in speciﬁc areas of the brain that are responsible for
responding to reward, such as the prefrontal cortex (Uylings et al.,
2003). Speciﬁcally, in baboons, complex cognitive functions and their
neuroanatomical substrates can be modelled and have demonstrated
to be highly reﬂective of humans in numerous tests (Zurcher et al.,
2010). Such functions associated with higher level frontal processing
are demonstrably close to those of humans. Relevant cognitive process-
es include the processing of orthographic symbols (reading English
words) (Grainger et al., 2012), analogical reasoning (Fagot and
Thompson, 2011), language processing (Medam and Fagot, 2016), and
cross-sensory modal integration (Martin-Malivel and Fagot, 2001). It
must be noted that these studies did not speciﬁcally study reward pro-
cessing, nevertheless they bolster the notion that high level cognitive
processes, such as reward processing, may be more conserved among
baboons and humans than they are disparate.
Rodent studies using fast scan cyclic voltammetry to measure the
amount of dopamine released as a function of positive RPE (when the
rewardwas greater than expected) and negative RPE (when the reward
was less than expected) demonstrated that dopamine release in the nu-
cleus accumbens correlated with magnitudes of the RPE (Hart et al.,
2014). In the rodent, the nucleus accumbens receives dopamine input
primarily from theVTA, indicating the rodent VTA is capable of signaling
both positive and negative RPE in the nucleus accumbens, but such
functional organization may not be true in primates (Section 2.6).
2.6. The source of dopamine release after a reward prediction error in NHPs
and humans
In 2007, Bayer and Glimcher found that in NHPs, both the frequency
and duration of bursts in the SNc correlated with the magnitude of pos-
itive RPE, and that the duration of SNc cell pauses correlated with the
magnitude of negative RPE (Bayer et al., 2007). Although the nucleus ac-
cumbens of both NHPs and rodents displayed a change in dopamine re-
lease during RPE, in the rodent this dopamine release is due solely to the
VTA neurons while in the NHP this dopamine release is dependent on
both VTA and SNc dopamine neurons (Fig. 2), and SNc ﬁring activity
correlates with negative RPE while VTA activity correlates with positive
RPE (Bayer et al., 2007) (Table 1).
This species-speciﬁc difference in the source of the RPE signal to the
nucleus accumbens may also extend to humans. Functional magnetic
resonance imaging studies demonstrated that the human nucleus ac-
cumbens also encodes positive and negative RPE. VTA neurons also
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and not to negative RPE (D'Ardenne et al., 2008). Thus, it is likely that
the signaling for negative RPE in the human nucleus accumbens is per-
formed by the SNc as it is in NHPs, but this has not been directly demon-
strated, as the role of the SNc in negative RPE has not been directly
investigated in humans.
2.7. Homotopic transplantation into the SNc
A putative solution to problems associated with heterotopic grafts
could be to transplant new dopamine neurons into the SNc rather
than into the striatum. It has been demonstrated that dopamine neu-
rons grafted homotopically into the SNc will successfully innervate the
striatum in the adult rodent brain (Thompson et al., 2009; Grealish et
al., 2010; Mendez et al., 2005; Gaillard et al., 2009). However, rodent
brain volumes are much smaller and contain disproportionately fewer
whitematter tracts than those of humans or NHPs (Table 1). Thus, stud-
ies are needed to explore the efﬁcacy and viability of homotopic SNc
transplantations in models that better represent the human brain.
NHPs provide an ideal resource for such studies in that not only are
their brain volumes (especially those of baboons) more similar to
humans, but the speciﬁc structural organization and size of the basal
ganglia in NHP brains is particularly homologous to that of humans
(Hardman et al., 2002) (Fig. 1). Collectively, the capacity to predict the
behavioral deﬁcits of PD-induced lesions in the SNc, and the potential
amelioration of deﬁcits following transplantation of new dopamine
neurons is likely to be difﬁcult due to disparities in the relevant neuro-
anatomy and patterns of response to environmental stimuli. As NHPs
provide the most accurate model of the human brain in these respects,
they represent the model that promises to yield maximally informative
and translatable preclinical data.
Of the commonly used laboratory old world primates (rhesus ma-
caque, green monkey, baboon), the baboon displays the greatest simi-
larity to the human in overall brain size (Herculano-Houzel, 2009),
glucose metabolism (Herculano-Houzel, 2011), and ratio of gray mat-
ter-to-white matter (Schoenemann et al., 2005; Zhang and Sejnowski,
2000; James et al., 1969; Leonard et al., 2008) (Table 1). Importantly
for development of PD therapies, the baboon SNc and other regions of
the basal ganglia are more similar to those in the human brain in both
size (Hardman et al., 2002) (Fig. 1) and density of TH+ neurons (Table
1) (Bjorklund and Dunnett, 2007) than are those of other NHPs includ-
ing rhesus macaques and marmosets. The baboon cerebral vasculature
also more closely resembles that of the human than does that of ma-
caques (D'Ambrosio et al., 2000; Thomas et al., 1993). For example,
the occipital/marginal venous system is present in baboons and
humans, but not in rhesus macaques (Aurboonyawat et al., 2007).
These similar neuroanatomical features render the baboon a particular-
ly relevant model for optimizing the surgical protocols employed for
stem cell therapies for PD.
3. The NHP model for transplantation therapy: immunological
considerations
iPS cells can be generated from any individual at any age, thus facil-
itating the availability of “patient-speciﬁc” iPS cell lines that should be
immunogenetically matched to the individual from which they were
derived (Takahashi et al., 2007; Hargus et al., 2010). However, the de-
gree of immunogenicity of differentiated derivatives of iPS cells upon
transplantation back into the individual from whom they were initially
derived remains a question (Bjorklund and Kordower, 2013; Morizane
et al., 2013; Guha et al., 2013; Araki et al., 2013; Zhao et al., 2011;
Mizukami et al., 2014; Lee et al., 2013; Kim, 2011; Lindvall et al., 2012;
Parmar and Bjorklund, 2012). For example, previous work in Macaca
fasicularis demonstrated that an autologous graft can survive transplan-
tation into a NHP brain (Morizane et al., 2013; Wang et al., 2015), and
provided proof-of-concept that patient-speciﬁc neurons can beproduced for the purposes of autologous transplantation therapy in pa-
tients with PD. However, in another study, only one of three Macaca
fasicularismonkeys that had received an autologous graft showed a sig-
niﬁcant reduction in lesion-associated motor deﬁcits (Hallett et al.,
2015), and therefore this aspect of a proposed stem cell-based approach
to the treatment of PD or any other disease should be further tested
in NHPs. In this section, we review the relevant immunological charac-
teristics of rodents, newworld primates, and oldworld primates as they
relate to humans. We pay particular attention to the response to acute
inﬂammatory insults and cyclosporin A (3.1), the homology in sequence
and function of the MHCs (3.2 and 3.3), and the effects of aging on the
immune system (3.4).
3.1. Immunological considerations: disparities between rodents and
humans
While rodents and humans share a great deal of similarity in the or-
ganization of the immune system (Haley, 2003; Bailey et al., 2013; Cho
et al., 2015; Plackett et al., 2003; Gelinas and McLaurin, 2005; Ferrari
et al., 2001), a growing body of literature suggests that immune systems
of rodents and humans differ in ways that signiﬁcantly hamper transla-
tion of results obtained in preclinical trials in rodents to successful
therapeutics in humans (Renshaw et al., 2002; Boehmer et al., 2004;
Rhoades and Orne, 1998; Swift et al., 2001; Rammos et al., 2014;
Wang et al., 2014; Bruhns, 2012; Rousseaux et al., 1983; Mestas and
Hughes, 2004). Rodents and humans respond differently to infectious
agents and possess disparate inﬂammatory responses (Leist and
Hartung, 2013; Tuomela and Lahesmaa, 2013). By 2011, N100 clinical
trials testing anti-inﬂammatory drugs that were effective in rodents
had failed in humans (Rice, 2012; Christaki et al., 2011). Typically,
b50% of genes shown to be differentially regulated in rodent models
of immune response (endotoxemia, trauma, and burn) are found to
change expression in humans exposed to the same inﬂammatory condi-
tions (Seok et al., 2013). When considering the genes that were differ-
entially expressed, the correlation coefﬁcient of the change in
expression between the two species was only 0.2 (Seok et al., 2013).
Further, mice do not possess the IgA FcαR1 receptor that speciﬁcally
binds IgA in humans. They also lack homologs to the human FcγRIIA
and FcγIIC receptors, which serve to mediate binding of immunoglobu-
lin G isotype 2 (IgG2) and IgG3 to neutrophils and ultimately affect sus-
ceptibility to infectious and autoimmune diseases in humans (Li et al.,
2013; Wolf et al., 2006; van Schie and Wilson, 2000).
Striking immunological distinctions between rodents and humans
are observed when microglia are examined. Microglia are the principle
mediators of the immune response in the central nervous system
(Kreutzber, 1996) and human microglia differ from those of rodents in
proliferative capacity, response to TGFβ signaling, expression of TNFγ
receptors and histocompatibility complexes (Kreutzber, 1996). Mestas
and Hughes (Mestas and Hughes, 2004) have provided a detailed re-
view of the functional differences in immune biology between mice
and humans.
Differences in immune function between rodents and NHPs may be
reﬂected in the immune response to tissues grafted for cell-therapies.
One study demonstrated a 6% survival rate for iPSC-derived neurons
transplanted into the brains of cyclosporin A -treated mice (Kriks et
al., 2011). This level of survival is higher than any known iPSC-derived
neuron transplantation into NHPs. However, when the same re-
searchers grafted neurons into cyclosporin A-treated rhesus monkeys,
they found that the injection sites contained large numbers of Iba1 pos-
itive microglia, which was indicative of a potent immune rejection
(Kriks et al., 2011). The authors of that study suggested that these pri-
mates suffered from persistent inﬂammation even though themonkeys
were immunosuppressed with cyclosporin A (Kriks et al., 2011). These
data were corroborated in another study in which a similar pattern of
inﬂammation and rejection of injected cells into cyclosporin A-treated
rodents and primates was observed (Gonzalez et al., 2015). These data
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and the proper administration of- immunosuppressants to prevent
graft rejections in NHPs.
3.2. Comparative sequence identity of the major histocompatibility com-
plexes among new world primates
The choice of an ideal animal model for studies of transplantation
procedures translatable to humans for treatment of PD (or other dis-
eases) depends on several considerations including the comparative or-
ganization and sequence identity of the MHCs. Clinical data have
conﬁrmed that matching MHC alleles between donor and host greatly
mitigates the risk of immune rejection of transplanted cells or organs
(Dunn et al., 2011; Rizzari et al., 2011; Vu et al., 2011; Held et al.,
1994). As such, MHC matching plays a crucial role in the acceptance or
rejection of any transplanted tissues (Magistris et al., 1992; Buus et al.,
1987). It follows that it will be preferable to conduct preclinical trans-
plantation studies using animal models that maximally recapitulate
the immunogenetic system of humans with respect to organization
and sequence variation in the antigen-binding domain of MHCs. To
that end, great effort has been directed toward characterizing the
MHC proteins of humans and various NHP species (Robinson et al.,
2015) including the common marmoset (Callithrix jacchus) (de Groot
et al., 2012; Antunes et al., 1998), pig-tailed macaque (Macaca
nemestrina) (Lafont et al., 2014), rhesus macaque (Macaca mulatta)
(Boyson et al., 1999), olive baboon (Papio anubis) (Prillman et al.,
1995), yellow baboon (Papio cyanocephalus) (Sidebottom et al., 2001),
chimpanzee (Pan troglodyte) (de Groot et al., 2000; Adams et al.,
2000) and others (de Groot et al., 2012). It should be noted here that
Papio cyanocephalus and Papio anubis are both subspecies of the genus
Papio, and likely possess highly related MHC proﬁles (Jolly, 1993;
Newman et al., 2004; Zinner et al., 2013).
New world primates, such as marmosets, have practical advantages
over old world primates as research models, including cost, size and
generation time (Ward and Vallender, 2012). However, phylogenetic
analyses ofMHC class I alleles in newworld primates includingmarmo-
sets and tamarins demonstrate that MHC class I genes cluster in a man-
ner that is distinct from those of old world primates or humans (Adams
and Parham, 2001;Watkins et al., 1993), and show an 82% identitywith
corresponding human leukocyte antigen (HLA; human equivalent of
MHC) alleles in humans (Robinson et al., 2015; Cadavid et al., 1997;
Shiina et al., 2011). Newworld primates also demonstrate reduced alle-
lic MHC variability in the antigen binding domains compared to that
found in old world primates and humans (Ward and Vallender, 2012;
Cadavid et al., 1997; Otting et al., 2002). Further, detailed comparisons
have demonstrated that MHC class II families in new world primates
are not orthologous to those of old world primates and that these
gene families may have evolved independently in new and old world
primates (Kriener et al., 2001). Lastly, comparative analyses of the IgG
isotypes demonstrated that new world monkey IgG subclasses cannot
be distinguished based on their binding to isotypic antigens that are ca-
pable of distinguishing human, hominidea, and baboon IgG subclasses,
suggesting that IgGs from newworldmonkeys are structurally different
from those of humans and baboons (Gaarder and Natvig, 1974). Thus,
signiﬁcant differences in the organization and function of genes
encodingMHC proteins and IgG isotypes in newworld primates render
these species less accurate models for testing potential adverse immu-
nogenetic responses to transplanted cells used in a cell based therapeu-
tic treatment for PD in humans.
3.3. Comparative sequence identity and functionality of the major histocom-
patibility complexes (MHC) and immunoglobulins among oldworld primates
Rhesusmacaques and baboons both share a high degree of sequence
similarity with humans, but do not have MHC-C loci (Messaoudi et al.,
2011; Moffett and Loke, 2006; Prillman et al., 1996). Depending on thespeciﬁc allele, rhesus macaques share an 80%–99% sequence identity
with humans at the HLA loci (Doerks et al., 2002). The baboon genome
is 90% homologous to the human genome at loci encoding MHC anti-
gens, while the regions for termini and the T-cell receptor binding
sites are nearly 99% homologous with the corresponding regions in
the human genome (Prillman et al., 1995). Also, unlike newworldmon-
keys, old world monkeys all express at least one HLA-A homologue, at
least one HLA-B homologue and a third HLA-A, -B, or -C homologue,
demonstrating conservation in the expression of MHC alleles between
humans and old world monkeys (Kennedy et al., 1997). However, the
rhesusmacaque is the animalmodel of choice for AIDS-related research
in the United States, and macaques with the MHC class I allele,
mamuA*01, are preferred because the reagents for such studies are
readily available. Thus, many rhesus macaques are bred to carry this al-
lele speciﬁcally, resulting in a reduced level of genetic heterogeneity at
the MHC class I loci compared to macaques found in the wild
(Kennedy et al., 1997; Viray et al., 2001).
Rhesusmacaques lack IgG3 (Shearer et al., 1999a; Calvas et al., 1999;
Martin, 1982), which shows the greatest degree of polymorphism (de
Lange, 1989), the strongest response to antigens at low concentrations,
and serves to activate the complement system (Michaelsen et al., 2009)
in humans. Additionally, macaque IgG1, IgG2, and IgG4 show a lower
(~83%) sequence homology at the amino acid level with the respective
human homologs than do the corresponding baboon IgGs (Calvas et al.,
1999). The baboon on the other hand, possesses all four IgG subclasses,
and these subclasses can be functionally identiﬁed by interaction with
the same isotypic antigens that characterize the IgG subclasses of the
human immune system (Gaarder and Natvig, 1974; Attanasio et al.,
2002; Damian et al., 1971). Further, the IgG subclasses share 87–90% se-
quence identity with their human counterparts (depending on the
isotype) at the amino acid level (Attanasio et al., 2002; Scinicariello et
al., 2002), and the immunoglobulin subclasses also share similar func-
tionality in baboons and humans. For example, in both species, IgG1
dominates the response to hepatitis B vaccination (Shearer et al.,
1999b) and Haemophilus inﬂuenza type B polysaccharide vaccination
(Shearer et al., 1997). The baboon also proved to be an effective model
for West Nile Virus, for which IgG and IgM are the primary mediators
of clearance in both humans and baboons, but not in macaques, which
are not susceptible to West Nile Disease (Wolf et al., 2006). Macaques
are also not susceptible to Bordetella pertussis infections, perhaps due
to an elevated body temperature (38.7–39.8 °C) compared to that of
humans (37 °C). Baboons have a body temperature (37.0–39.0 °C) clos-
er to that of humans, and have proven to be excellentmodels for studies
involving Bordetella pertussis (Merkel and Halperin, 2014; Fernandez,
2012).
3.4. The aging immune system
Therapies for neurodegenerative diseases are often additionally
complicated by the fact that patients receiving such therapies are ad-
vanced in age. Patients N60 years old have a lower risk of acute graft re-
jection than younger patients (reviewed in Tullius and Milford (2015),
but have a signiﬁcantly increased risk of chronic graft failure and immu-
nosuppressant-induced nephrotoxicity (Heinbokel et al., 2013; Martins
et al., 2005). Thismay be because the immune systemof aged patients is
different from that of younger patients in several ways. Aged humans
demonstrate increased autoantibody production and autoinﬂammatory
response (Rowley et al., 1968) such that it is possible aged patients may
elicit a substantially different immune response to transplanted cells
than younger patients, even when autologous, patient-speciﬁc iPS-de-
rived cells are used. Patients aged 65 and older have increased levels
of proinﬂammatory cytokines such as C reactive peptide (CRP), IL-6
(Harris et al., 1999), IL-8 (Mariani et al., 2002), IL-1, IL-10, and TNF-α
(Rink et al., 1998; Brüünsgaard and Pedersen, 2003). Humans also dem-
onstrate an age-related decrease in anti-inﬂammatory cytokines, such
as TGF-ß1 (Okamoto et al., 2005) and DHEA (Hazeldine et al., 2010)
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recipients is unknown, but the aforementioned changes in cytokine
levels have been suggested to play a role (Martins et al., 2005). Further,
immune senescence is particularly relevant in the case of PD as the high
level of reactive oxygen species associated with PD is known to exacer-
bate age-related increases in inﬂammatory cytokine production via
NFκB signaling (Gloire et al., 2006).
In the common marmoset (a new world monkey), neither CRP nor
IL-8 levels vary with age (Tardif et al., 2011), and the relationship be-
tween age and the expression of other critical inﬂammatory cytokines,
such as IL-6 and IL-10, is unknown. In the rhesusmacaque, the aging im-
mune system is ostensibly concordant with that of humans. Aging
rhesus macaques demonstrate increasing levels of IL-10, which is simi-
lar to humans, but unlike humans, rhesus macaques do not show age-
related increases in IL-1, IL-6, or TNF-α (Mascarucci et al., 2001). Con-
versely, rhesus macaques display an age-related decline in IL-6 and
TNF-α (Asquith et al., 2012), a pattern that is opposite of that observed
in aging humans (Table 1). Aged baboons do demonstrate increased
production of autoantibodies (Attanasio et al., 2001), IL-6, and CRP
(McFarlane et al., 2011), in a manner similar to humans, but not IL-10
(McFarlane et al., 2011). Also as in the human, levels of TGFβ1 and
DHEA decrease as a function of aging in the baboon (Willis et al.,
2014) (Table 1), whereas these changes are not known to take place
in rhesus, suggesting that results discovered in cell transplantation
studies involving aged baboons will more accurately predict the extent
of immune reactions to cell grafts in aged humans. Species differences in
cytokine regulation, and their impact on clinical experimentationwas il-
lustrated in the preclinical testing of TGN1412, an anti-CD28 antibody
designed to suppress immune response independently of CTLA-4.
While TGN1412 showed successful results in preclinical trials in the ro-
dent and rhesus macaque, administration to humans in phase I clinical
trials resulted in a cytokine storm and cytokine release syndrome
(Suntharalingam et al., 2006). Later investigations found that this was
due to effector memory T-cells that are activated by CD28 antibodies
in humans, but not in rhesusmacaques. This is because effectormemory
T-cells in rhesus do not express the appropriate receptor for CD28. Ex-
periments on TGN1412 in the baboon, however, were later able to reca-
pitulate the results found in humans (Poirier et al., 2014), and since
then, the baboon has been the NHPmodel of choice for immunotherapy
experimentation (Poirier et al., 2016).
Finally, the baboon has also been used heavily for preclinical drug
trials because the activity of the blood brain barrier transport protein,
P-glycoprotein, is highly reﬂective of that in humans (Chu et al., 2013;
Syvanen et al., 2009). Because of this and the similarities between the
baboon and human immune systems noted above (Table 1), psycho-
pharmacological studies of blood brain barrier penetrance in baboons
(Blin et al., 1988; Villemagne et al., 1998) have been shown to be predic-
tive of outcomes of the same psychopharmacological treatments in
humans even where other NHPs have failed to adequately predict
human outcomes (Hou et al., 2014; Volkow et al., 2001; Ding et al.,
1997; Volkow et al., 1998). The combination of these features renders
the baboon a particularly useful model for studies investigating immu-
nosuppressive regimens for the tolerance of cell grafts designed to
treat neurodegenerative diseases such as PD.
4. Nonhuman primate models for transplantation therapy: motor
and non-motor manifestations of the MPTP lesion
Methods that have been used to induce a parkinsonian state in NHPs
include 1-methyl-4-phenyl-1,2,3,6 tetrahydropyridine (MPTP) admin-
istration (Emborg, 2007), 6-hydroxydopamine administration
(Ungerstedt, 1968), and transduction with viral vectors to promote ex-
pression of speciﬁc proteins such as alpha synuclein (Orth et al., 2003;
Decressac et al., 2011). Compared to other lesion-basedmodels of PD in-
cluding rotenone, paraquat, and 6-hydoxydopamine (Tanner et al.,
2011), systemic administration of MPTP is most directly linked tohuman PD and the most common method to phenocopy PD in animal
models (Langston et al., 1983; Langston, 1985). MPTP metabolites are
taken up by dopamine neurons via the dopamine transporter and
then function as an inhibitor to complex I of the mitochondrial respira-
tory chain in these cells (Schapira et al., 1989). For reasons that remain
undetermined, dopamine neurons from the SNc are especially vulnera-
ble to MPTP (Hantraye et al., 1993; Johannessen et al., 1985; German et
al., 1992). Thus, the result of MPTP treatment is a neurodegenerative
state that is similar to PD. In this section we review the consequences
of MPTP induced lesions in rodents (4.1) and NHPs (4.2), including
manifestation of both motor and non-motor symptoms.
4.1. Motor and non-motor manifestations of the MPTP lesion in rodents
Mice and rats are signiﬁcantly less sensitive to the deleterious
effects of MPTP than primates and humans (Muthane et al., 1994;
Dauer and Przedborski, 2003). To obtain the full range of neuronal def-
icits observed in NHPs, mice require dosages reported to be as high as
30 mg/kg/day (cumulative dose of 300 mg/kg) (Johannessen et al.,
1985; Seniuk et al., 1990). Thus, at doses much higher than those ad-
ministered to primates, midbrain dopamine cells can also be lesioned
in the rodent with MPTP (Bannon et al., 2015), resulting in motor
deﬁcits. Assays of motor deﬁcits in MPTP-lesioned rodents are robust
in tests of gross motor movement, such as walking a balance beam
(Sharma and Deshmukh, 2015) or running on an exercise wheel
(Sconce et al., 2015) (Table 1). However, resolving symptoms of PD
such as resting tremor and bradykinesia have proven more difﬁcult in
rodents, and studies have produced conﬂicting results about whether
or not such deﬁcits exist in MPTP treated rodents (Sedelis et al.,
2001a,b; Salamone et al., 1998; Ferro et al., 2005).
4.2. Motor and non-motor manifestations of the MPTP lesion in new world
and old world monkeys
MPTP has been used to create PD-like symptoms in many NHPs, in-
cluding the squirrelmonkey (DiMonte et al., 2001), commonmarmoset
(Kupsch et al., 2001), cynomolgus monkey (Brownell et al., 1998),
rhesus macaque (Wichmann et al., 1999), and olive baboon (Hantraye
et al., 1993; Varastet et al., 1994). Although the particular dosage
administered to an animal depends on the route of administration
and the experimental design (acute or chronic lesion), MPTP dosages
for NHPs are typically reported at 3 mg/kg/day (cumulative dose
of 15–30 mg/kg) in marmosets (Rose et al., 1993), 3 mg/kg/day in
squirrel monkeys (Forno et al., 1986), 1.2 mg/kg/day (cumulative dose
of 1.2–7.8 mg/kg) in rhesus macaques (Johannessen et al., 1985;
Ovadia et al., 1995; Fifel et al., 2014), and 0.1 mg/kg/day (cumulative
dose of 11–40 mg/kg) in the baboon (Varastet et al., 1994; Hantraye
et al., 1993). There are only three reported cases of MPTP exposure in
humans, and the dosages could not be determined absolutely, but
estimates suggest that cumulative dosages of 6–12 mg/kg were
sufﬁcient to induce permanent neuronal degeneration in the SNc of
humans (Langston et al., 1999). These values are much lower than
those reported for rodents, and the differential susceptibility to MPTP
seen in rodents and primates may be due to differential metabolism of
MPTP (Johannessen et al., 1985), lower expression of speciﬁc dopamine
transporters that transport MPTP in rodents (Shimohama et al., 2003),
differential cellular composition of the SNc in rodents and primates
(Muthane et al., 1994), and/or the fact that midbrain dopamine cells
of the rodent do not contain the pigment, neuromelanin, which is
found in primate dopamine cells and enhances the toxicity of MPTP
(Herrero et al., 1993). NHP models are advantageous in that their long
life spans allow for chronic administration of low-doses of MPTP,
which better reﬂects the chronic pathogenesis of PD in humans
(Hantraye et al., 1993; Smith et al., 1992; Bezard et al., 1997; Meissner
et al., 2003). Similar to humans suffering from PD, NHP MPTP models
demonstrate cognitive deﬁcits (Schneider and Pope-Coleman, 1995;
361D.A. Grow et al. / Stem Cell Research 17 (2016) 352–366Schneider and Kovelowski, 1990; Schneider and Roeltgen, 1993;
Roeltgen and Schneider, 1994) and loss of dopamine neuron innerva-
tion in extrastriatal targets such as the globus pallidus (Jan et al.,
2000) and the prefrontal cortex (Brozoski et al., 1979; Aron Badin et
al., 2015) – symptoms that are not observed in rodent models (see
above Sections 2.1 and 2.2) (Table 1).
Speciﬁcally in baboons, chronic administration ofMPTP induces a se-
lective destruction of dopaminergic neurons in the caudal and ventro-
lateral regions of the SNc (Varastet et al., 1994), a pattern that has
otherwise only beennoted in cases of human PD (Kish et al., 1988). Sim-
ilar to both marmosets and rhesus, baboons also demonstrate the full
range of symptoms associated with parkinsonism including rigidity,
resting tremor, bradykinesia (Hantraye et al., 1996; Viallet et al.,
1981), postural instability (Hantraye et al., 1993; Drouot et al., 2004),
and aggregation of alpha synuclein (Kowall et al., 2000).
As noted above (Section 1), victims of PD suffer from non-motor
symptoms such as cognitive impairment (Litvan et al., 2012), depres-
sion, fatigue, and sleep disorders (Chaudhuri and Schapira, 2009) that
are not observed in MPTP treated mice (Laloux et al., 2008). Despite
the fact that non-motor symptoms of PD have been observed as early
as 1975 (Ansari and Johnson, 1975), they have only recently begun to
receive attention in the scientiﬁc community (Shulman et al., 2002;
Goetz et al., 2003). For example, clinical assessment of non-motor
symptoms was not added to the Uniﬁed Parkinson's Disease Rating
Scale until 2008 (Goetz et al., 2008). As a result, there are currently no
studies that investigate the ability of cell-based therapies to treat the
non-motor aspects of PD. However, based on the fact that NHP models
of PD and humans with PD present with non-motor symptoms that
are absent in rodent models of PD (Table 1), future studies aiming to
test the ability of cell-based therapies to treat non-motor symptoms
should be carried out in NHPs. MPTP-induced models of PD in NHPs
such as the marmoset (Collins et al., 2000) and rhesus (Fifel et al.,
2014; Schneider and Pope-Coleman, 1995; Schneider and Kovelowski,
1990) have demonstrated many of these same non-motor symptoms,
including cognitive deﬁcits (Schneider and Roeltgen, 1993; Decamp
and Schneider, 2004), activated microglia (Barcia et al., 2004), and
disruptions in circadian rhythms (Fifel et al., 2014). Baboons display
behavioral and cognitive abilities correlative to those of humans
(Fagot and Paleressompoulle, 2009; Goujon and Fagot, 2013), and
exhibit cognitive deﬁcits when administered MPTP (Hantraye et al.,
1996) (Table 1). Baboons also demonstrate other non-motor Parkinso-
nian symptoms such as age-related loss of dopamine compensation
(Duong, 2010).
5. The baboon as an optimal model for cell-based therapies for PD
In this review, we have presented a detailed comparison of NHP bi-
ology with respect to the neuroanatomical, neurophysiological, immu-
nological features pertinent to studying the transplantation of iPSC-
derived neurons for treatment of PD. NHPs in general, and baboons in
particular, offer considerable advantages over rodents asmodel systems
for preclinical studies to optimize the efﬁcacy and safety of a cell-based
approach to the treatment of PD. Among NHPs, old world monkeys are
particularly valuable for use in neurological transplantation studies be-
cause they share critical neuroanatomical commonalities with humans,
including physical separation of the nuclei of the striatum (Bove and
Perier, 2012), which is the primary target of SNc neurons, and a
gyrencephalic brain (Wu et al., 2012). Old world monkeys also demon-
strate age-related loss of TH+ neurons in the SNc and a correlated de-
cline of motor and cognitive skills (Emborg et al., 1998). These age-
related changes are not observed in new world monkeys (McCormack
et al., 2004). Of the old world genera, rhesus macaques (Macaca
mulatta) are the most commonly used NHP species in biomedical re-
search, but are in high demand for HIV/AIDS studies. In contrast, the ba-
boon is widely available and is equally homologous to humans at the
genomic level as the rhesus, with both possessing genomes with atleast 92% sequence identity to the human genome (Caccone and
Powell, 1989; Rogers and Hixson, 1997).
However, the advantages of NHPmodels are notwithout costs. Stud-
ies using NHPs typically require greater time to complete than those
using rodents. With respect to PD, this includes the time needed to cre-
ate a stable lesion in the primate using MPTP and the time required to
observe a stable recovery post-transplantation. For example, injection
of 6-hydroxydopamine directly into the rodent SNc can effectively ab-
late the SNcwithin 1–3 days (Hokfelt and Ungerstedt, 1973). It is possi-
ble to use MPTP to lesion the SNc of a NHP within one week via
intracarotid injections (Emborg et al., 2008) or high doses of systemical-
ly injected MPTP (Gonzalez et al., 2015). However, such methods often
produce unwanted toxicity and highly variable lesions. The use of MPTP
to create a stable lesion in NHPs requires administration of low doses
over a period of two to three months (Drouot et al., 2004) with regular
assessments for a period of six months to a year to ensure there is no
spontaneous recovery (Potts et al., 2014). Following cell transplantation
intomice, a stable recovery can typically be observed within onemonth
(Gaillard and Jaber, 2011). In NHPs such as the baboon, however, motor
activity does not return to baseline until at least six months after trans-
plantation (Hallett et al., 2015). Thus, it could take 14–28months to ob-
serve both a stable lesion-induced motor deﬁcit and a stable graft-
mediated recovery in baboons.
Experiments in NHPs can also be more technically challenging than
those carried out in rodents. For example,MPTP is a highly toxic reagent
and animals exposed to it need to be housed in biosafety level 2 labora-
tories and cared for by highly trained staff. Further, although a stereo-
tactic atlas does exist for baboon brains (Davis and Huffman, 1968),
the presence of variation in brain volumes among baboons (Rogers et
al., 2007; Davis and Huffman, 1968) typically requires that precise loca-
tion of the injection sites should be determined usingMRI (Jarraya et al.,
2009). Finally, lengthy experiments involving NHPs incur signiﬁcant ﬁ-
nancial costs.
However, despite the costs associated with the use of NHPs in bio-
medical research, preclinical studies using NHP models are necessary
to validate the efﬁcacy and safety of novel cell-based therapeutic proce-
dures prior to translation of these approaches to the clinic. Multiple ex-
amples now exist of efforts to translate methodology directly from
rodent models to the clinic with little or no success (Leist and
Hartung, 2013; Rice, 2012; Christaki et al., 2011; Seok et al., 2013;
Courtine et al., 2007; Donahue and Dunbar, 2001). While experiments
carried out in NHPs are ﬁnancially costly, they are many times less ex-
pensive than clinical trials. Indeed, the costs of such failed efforts to
translate protocols directly from rodent models to the clinic can easily
exceed the costs of well-planned preclinical studies involving NHP
models that can signiﬁcantly enhance the likelihood of successful clini-
cal translation. Thus, efforts to avoid costs by avoiding theuse of clinical-
ly relevant NHP models to validate the efﬁcacy of cell-based therapies
can potentially result in higher costs in the long run. And this problem
will be magniﬁed exponentially if a protocol developed in rodent
models and translated directly to the clinic leads to unwanted off-target
effects that may accrue uniquely in primates – such as the induction of
tumorigenesis.
Rodent models and models involving other smaller mammals (e.g.
rabbits or pigs) afford signiﬁcant experimental power both in terms of
the number of replicate animals that can be investigated and the
many research models available, especially in the mouse. Thus, the
ideal scenario for development of novel stem cell-based therapies for
the treatment of PD or other complex diseases will likely involve initial
studies in rodent and other small mammal models to develop initial
protocols – followed by testing in the more clinically relevant NHP
models to validate the efﬁcacy and safety of each protocol and/or to
modify the protocol as needed prior to translation to the clinic.
AmongNHPmodels available for studies of cell-based approaches to
the treatment of PD, we have summarized the advantages of the ba-
boon. The baboonwas the ﬁrst NHP for which a detailed genetic linkage
362 D.A. Grow et al. / Stem Cell Research 17 (2016) 352–366map was generated (Cox et al., 2013), and the baboon genome is now
largely complete and available (https://www.hgsc.bcm.edu/baboon-
genome-project-0). The Southwest National Primate Research Center
currently houses baboons with well documented pedigrees spanning
eight or more generations, with genotyping data and banked biomate-
rials that represent a unique resource for tracing heritable contributions
to disease progression. These assets will facilitate genetic studies to de-
ﬁne the extent of relatedness among donors and recipients required for
successful cell-based therapeutic approaches, as well as studies at the
genomic level to further conﬁrm the functionality of cells prior to and
following transplantation. Taken together, the many advantages de-
scribed in this review establish NHPs in general, and the baboon in par-
ticular, as optimal, penultimate preclinical models with which to
validate the utility of each speciﬁc protocol prior to transitioning that
protocol to clinical use.
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